TG Therapeutics Inc (TGTX) Balance Sheet
A balance sheet shows what a company owns and owes, and shareholders' equity, at a single point in time.
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally.
Total Assets Chart for TG Therapeutics Inc
TG Therapeutics Inc (TGTX) total assets for FY2025 were USD 1.1B, a 84.1% change from FY2024. TG Therapeutics Inc's total assets grew from USD 2.4M in 1996 to USD 1.1B in 2025 (44202.2% over 29 years). Total assets compound annual growth rate: 5-year CAGR of 11.2%, 10-year CAGR of 25.1%, 20-year CAGR of 25.6%.
Total Assets (US Dollars)
R&D as % of Revenue
Compare with
Key Stats
- Market Cap
- $8.29B
- Implied Share Price
- $54.17
- Enterprise Value
- $8.75B
- Revenue (TTM)
- $799.54M
- EBITDA
- $136.45M
- Profit Margin
- 55.22%
- Trailing P/E
- 19.70
- Forward P/E
- 25.84
- Price/Book (MRQ)
- 14.15
- Price/Sales (TTM)
- 10.37
- EV/EBITDA
- 62.77
- EV/Revenue
- 10.94
- Dividend Yield
- —
- Book Value
- $4.26
- Free Cash Flow (FY2025)
- -$24.99M
- Free Cash Flow Yield
- -0.30%
Snapshot as of 24th October 2026 — not point-in-time controlled, may lag the live market by a few days.